New frontiers in anticoagulation: non vitamin-K oral anticoagulants in stroke prevention

被引:1
|
作者
Arnao, Valentina [1 ,2 ]
Riolo, Marianna [1 ]
Tuttolomondo, Antonino [3 ]
Pinto, Antonio [3 ]
Fierro, Brigida [1 ]
Aridon, Paolo [1 ]
机构
[1] Univ Palermo, BioNeC Dipartimento BioMed Sperimentale & Neurosc, Palermo, Italy
[2] Univ Palermo, Sch Med Clin & Sci Comportamento, Biomed Dept Internal & Specialist Med Di Bi MIS, Palermo, Italy
[3] Univ Palermo, Biomed Dept Internal & Specialist Med Di Bi MIS, Palermo, Italy
关键词
Anticoagulation; atrial fibrillation; measure of monitoring; stroke prevention; reverse therapy; non vitamin-K oral anticoagulants; warfarin; aspirin; NONVALVULAR ATRIAL-FIBRILLATION; THROMBIN INHIBITOR DABIGATRAN; ASSAYS LABORATORY RECOMMENDATIONS; ANTITHROMBOTIC THERAPY; UNDETERMINED SOURCE; COAGULATION ASSAYS; INTRAVENOUS THROMBOLYSIS; ACETYLSALICYLIC-ACID; PROTHROMBIN TIME; ISCHEMIC-STROKE;
D O I
10.1080/14737175.2017.1268053
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: Non vitamin-K oral anticoagulants (NOACs) are direct and specific inhibitors of the coagulation factors IIa (dabigatran) and Xa (apixaban, rivaroxaban, edoxaban) which share many pharmacokinetic properties. However, indications are lacking regarding the use of NOACs during thrombolysis, surgery and bleeding events.Areas covered: In this paper, the authors retrospectively analyzed the relevant literature on the NOACs using the PubMed and Google Scholar databases.Expert commentary: Although warfarin is effective in cardioembolic stroke prevention, easier handling and more favorable risk-benefit profile often render NOACs a more preferable therapy choice for neurologists. New evidences have suggested their use in treatment of elderly people, in patients with renal insufficiency or with antiphospholipid antibody syndrome. In addition, the use of antidotes, which rapidly reverse the anticoagulant effect of the NOACs, could be useful in bleeding, during emergency procedures, or in case of overdose.
引用
收藏
页码:539 / 552
页数:14
相关论文
共 50 条
  • [41] Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants
    Hillis, Christopher M.
    Crowther, Mark A.
    THROMBOSIS AND HAEMOSTASIS, 2015, 113 (06) : 1193 - 1201
  • [42] The impact of non-vitamin K antagonist oral anticoagulants (NOACs) on anticoagulation therapy in rural Australia
    Bellinge, Jamie W.
    Paul, Jarrad J.
    Walsh, Liam S.
    Garg, Lokesh
    Watts, Gerald F.
    Schultz, Carl
    MEDICAL JOURNAL OF AUSTRALIA, 2018, 208 (01) : 18 - 23
  • [43] Oral Anticoagulation in Japanese Patients With Atrial Fibrillation - Insight to the Use of Non-Vitamin K Antagonist Oral Anticoagulants
    Gomez-Molina, Miriam
    Valdes, Mariano
    Marin, Francisco
    CIRCULATION JOURNAL, 2015, 79 (02) : 292 - 294
  • [44] Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation
    Briere, Jean-Baptiste
    Bowrin, Kevin
    Millier, Aurelie
    Toumi, Mondher
    Wojciechowski, Piotr
    Taieb, Vanessa
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (08) : 760 - 765
  • [45] OVERVIEW OF NON-VITAMIN K ORAL ANTICOAGULANTS
    Cirstea, Iulia Madalina
    Mindrila, Bogdan
    Tieranu, Eugen
    Tieranu, Loredana Maria
    Istratoaie, Octavian
    Militaru, Constantin
    Donoiu, Ionut
    FARMACIA, 2020, 68 (02) : 206 - 212
  • [46] Occurrence of Ischemic Stroke in Patients With Atrial Fibrillation Receiving Non-Vitamin K Oral Anticoagulants: Causes and Prevention Strategies
    Bang, Oh Young
    Park, Kyoung-Min
    Jeong, Dong Seop
    JOURNAL OF STROKE, 2023, 25 (02) : 199 - 213
  • [47] Improved Stroke Prevention in Atrial Fibrillation After the Introduction of Non-Vitamin K Antagonist Oral Anticoagulants The Stockholm Experience
    Forslund, Tomas
    Komen, Joris J.
    Andersen, Morten
    Wettermark, Bjorn
    von Euler, Mia
    Mantel-Teeuwisse, Aukje K.
    Braunschweig, Frieder
    Hjemdahl, Paul
    STROKE, 2018, 49 (09) : 2122 - 2128
  • [48] Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants
    Turagam, Mohit K.
    Velagapudi, Poonam
    Flaker, Greg C.
    CLINICAL INTERVENTIONS IN AGING, 2015, 10 : 1431 - 1444
  • [49] Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: Time for a reappraisal
    Lip, Gregory Y. H.
    Wang, Kang-Ling
    Chiang, Chern-En
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2015, 180 : 246 - 254
  • [50] Risk Factors for Intracerebral Hemorrhage in Patients With Atrial Fibrillation on Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention
    Paciaroni, Maurizio
    Agnelli, Giancarlo
    Giustozzi, Michela
    Caso, Valeria
    Toso, Elisabetta
    Angelini, Filippo
    Canavero, Isabella
    Micieli, Giuseppe
    Antonenko, Kateryna
    Rocco, Alessandro
    Diomedi, Marina
    Katsanos, Aristeidis H.
    Shoamanesh, Ashkan
    Giannopoulos, Sotirios
    Ageno, Walter
    Pegoraro, Samuela
    Putaala, Jukka
    Strbian, Daniel
    Sallinen, Hanne
    Mac Grory, Brian C.
    Furie, Karen L.
    Stretz, Christoph
    Reznik, Michael E.
    Alberti, Andrea
    Venti, Michele
    Mosconi, Maria Giulia
    Vedovati, Maria Cristina
    Franco, Laura
    Zepponi, Giorgia
    Romoli, Michele
    Zini, Andrea
    Brancaleoni, Laura
    Riva, Letizia
    Silvestrelli, Giorgio
    Ciccone, Alfonso
    Zedde, Maria Luisa
    Giorli, Elisa
    Kosmidou, Maria
    Ntais, Evangelos
    Palaiodimou, Lina
    Halvatsiotis, Panagiotis
    Tassinari, Tiziana
    Saia, Valentina
    Ornello, Raffaele
    Sacco, Simona
    Bandini, Fabio
    Mancuso, Michelangelo
    Orlandi, Giovanni
    Ferrari, Elena
    Pezzini, Alessandro
    STROKE, 2021, 52 (04) : 1450 - 1454